Curadev is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics aimed at treating intractable diseases. The company employs a target-centric approach combined with classical medicinal chemistry and innovative screening techniques to create new medicines. Their research portfolio includes patent-protected drug candidates that target next-generation drug mechanisms, particularly in areas such as immune oncology, neuroinflammation, and fibrotic diseases. Curadev's commitment to advancing drug discovery is exemplified by their ongoing clinical trials, including a Phase 1a/b trial of their allosteric STING agonist, CRD3874-SI, for patients with advanced cancer.

In the realm of neuroinflammation, Curadev is actively investigating the role of microglia, the primary immune cells in the central nervous system, which are crucial for immune surveillance and developmental processes. The company has established a collaboration with INSERM’s Hôpital Robert Debré in Paris to explore the link between microglia-driven neuroinflammation and various neuropathologies. This partnership enhances Curadev's capabilities in target identification for autoimmune diseases and cancers, providing access to advanced research and in-vivo disease models. Through these efforts, Curadev aims to address the challenges of modulating microglial activity to develop effective treatments for neuroinflammatory conditions.

India

Curadev - We are a small molecule drug discovery biotech with an exciting portfolio of research programs that have yielded patent protected drug candidates. Founded in 2010, Curadev has created a premier translational research organization known for prescient target selection and high quality, data-driven program execution. Our programs seek to ameliorate disease by translating cutting edge discoveries into new medicines. We have swiftly established our credentials by successfully creating and out-licensing our small molecule patents in immune-oncology.

Curadev

Company Details